Ashwagandha and Antidepressants: Interactions and Cautions

Ashwagandha and Antidepressants is a question that comes up frequently in our inbox at Bio:sudo. Patients taking SSRIs, SNRIs, or other psychiatric medications want to know whether adding this Ayurvedic adaptogen is safe, beneficial, or risky. The short answer: the interaction is poorly studied in controlled trials, and the decision should be made with your prescribing clinician. This article reviews what the human evidence actually says about ashwagandha's effects on stress and anxiety, how its mechanisms might overlap with antidepressant pathways, and what cautions apply when the two are combined.

What the Human Evidence Actually Shows

The clinical literature on ashwagandha (Withania somnifera) for mood and anxiety is growing, but it is not specifically designed to study patients already on antidepressants. Most trials exclude participants taking psychiatric medications, which means we have limited direct data on combination use.

The strongest human evidence comes from randomized controlled trials (RCTs) in adults with chronic stress or generalized anxiety. Chandrasekhar et al. (2012) conducted a 60-day double-blind RCT in 64 adults with chronic stress. Participants receiving 300 mg of a high-concentration full-spectrum root extract twice daily showed significant reductions in serum cortisol and subjective stress scores compared with placebo. Notably, this trial excluded participants on psychotropic medications, so no interaction data was collected. Chandrasekhar 2012

Langade et al. (2019) tested ashwagandha root extract at 300 mg twice daily for 10 weeks in adults with insomnia and anxiety. The treatment group improved on sleep quality and anxiety measures, but again, the study protocol excluded participants with diagnosed psychiatric disorders or those taking antidepressants. Langade 2019

Pratte et al. (2014) published a systematic review of human trials for ashwagandha and anxiety. Of the five trials meeting inclusion criteria, all reported positive outcomes, but the authors noted significant heterogeneity in extract types, dosing, and outcome measures. They explicitly flagged the lack of drug-interaction data as a major gap. Pratte 2014

There are no published RCTs, to our knowledge, that randomize participants on stable antidepressant regimens to ashwagandha versus placebo. This absence of data is the central limitation when evaluating Ashwagandha and Antidepressants together.

How Ashwagandha Works in the Brain

Ashwagandha's bioactive compounds—primarily withanolides, withaferin A, and sitoindosides—modulate several neurochemical systems relevant to mood regulation. Understanding these mechanisms helps explain why theoretical interaction concerns exist.

GABA Receptor Modulation

Preclinical studies suggest withanolides enhance GABAergic signaling, which is calming and anxiolytic. Many antidepressants, particularly benzodiazepines (though these are anxiolytics rather than antidepressants), and some adjunctive therapies also target GABA pathways. The concern is not additive toxicity but additive sedation or cognitive slowing if combined.

HPA Axis and Cortisol

Ashwagandha is best characterized as an HPA-axis modulator. It lowers cortisol in chronically stressed adults, as demonstrated by Chandrasekhar et al. (2012). Some antidepressants, especially SSRIs, also affect cortisol dynamics over time. The theoretical risk here is not acute interaction but a compounded effect on hypothalamic-pituitary-adrenal axis function, which could be relevant in patients with adrenal insufficiency or those tapering steroids.

Serotonergic and Dopaminergic Effects

Animal and in vitro data suggest withanolides may influence serotonin and dopamine receptor density or neurotransmitter levels. If these preclinical findings translate to humans, there is a theoretical risk of serotonin syndrome when combined with SSRIs or SNRIs. However, human clinical trials have not reported serotonin syndrome events, and the serotonergic effect of ashwagandha appears weak compared with pharmaceutical antidepressants. This remains a theoretical caution, not an established contraindication.

Thyroid Hormone Interaction

Ashwagandha has been shown in some studies to increase thyroid hormone levels (T3 and T4) while lowering TSH. This is relevant because both hyperthyroidism and hypothyroidism affect mood, and some antidepressants (notably lithium and certain TCAs) influence thyroid function. Patients on thyroid medication or mood stabilizers should be especially cautious.

Key Clinical Trials at a Glance

<

Study	Population	Extract / Dose	Duration	Key Outcome	Psych Med Exclusion?
Chandrasekhar et al. (2012)	64 adults with chronic stress	Full-spectrum root extract, 300 mg × 2/day	60 days	↓ Cortisol; ↓ Perceived stress	Yes
Langade et al. (2019)	60 adults with insomnia and anxiety	Root extract, 300 mg × 2/day	10 weeks	↑ Sleep quality; ↓ Anxiety scores	Yes
Wankhede et al. (2015)	57 healthy resistance-trained men	Root extract, 300 mg × 2/day	8 weeks	↑ Muscle strength; ↑ Testosterone	Not specified
Choudhary et al. (2017)	50 adults with mild cognitive impairment	Root extract, 300 mg × 2/day	8 weeks	↑ Memory; ↑ Executive function	Yes
Pratte et al. (2014) — Review	5 RCTs summarized	Various extracts, 300–600 mg/day	6–12 weeks	Consistent anxiolytic signal	Varied

One pattern is clear: the 300 mg twice-daily dosing of standardized root extract appears consistently across positive trials. This is the dose range used in products like Bio:sudo KSM-66 Reishi Restore, which delivers a full-spectrum KSM-66 extract combined with reishi for additional adaptogenic support. However, if you are on an antidepressant, dose consistency matters less than clinician oversight.

What the Evidence Does Not Show

It is equally important to clarify what has not been demonstrated. No published trial has shown that ashwagandha augments antidepressant efficacy in patients with major depressive disorder. No trial has shown it reduces antidepressant side effects. No pharmacokinetic study has mapped how ashwagandha extracts alter the metabolism of fluoxetine, sertraline, venlafaxine, or bupropion.

Case reports in the medical literature describe rare adverse events when herbal supplements are combined with psychiatric medications, but these are anecdotal and often involve multi-herb regimens or poor-quality extracts. They cannot establish causality. The absence of robust interaction data means we must rely on mechanistic plausibility and clinical caution rather than evidence-based contraindications.

For a broader overview of how supplements and pharmaceuticals can interact, see our guide on Supplement and Drug Interactions: What Every Supplement User Should Know.

Specific Scenarios and Caution Levels

SSRIs (e.g., Sertraline, Fluoxetine, Escitalopram)

Theoretical serotonin interaction risk is low to moderate. No documented cases of serotonin syndrome with ashwagandha alone exist, but the combination has not been formally tested. If a patient is stable on an SSRI and wishes to try ashwagandha, a cautious approach is to start low, monitor for agitation, tremor, or sweating, and involve the prescribing psychiatrist.

SNRIs (e.g., Venlafaxine, Duloxetine)

Dual serotonin and norepinephrine reuptake inhibition raises the theoretical interaction profile slightly. Ashwagandha's modest effects on catecholamine pathways could, in theory, overlap. Again, human data is absent. Clinical monitoring is prudent.

Bupropion (NDRI)

Bupropion is dopaminergic and noradrenergic, not serotonergic. The interaction profile with ashwagandha is unclear. Both compounds can be activating. Patients report mixed experiences—some find the combination helpful for fatigue, others experience overstimulation. This is anecdotal and should not guide clinical decisions.

MAOIs and TCAs

These older antidepressant classes have broader receptor profiles and higher interaction risk in general. The combination with ashwagandha is not recommended without direct physician supervision, given the lack of safety data and the narrow therapeutic index of MAOIs in particular.

Tapering or Discontinuation Contexts

Some patients explore ashwagandha while tapering antidepressants. This is a high-risk window. Withdrawal symptoms can mimic anxiety or insomnia, and adding a new supplement complicates attribution. We do not recommend initiating ashwagandha during active tapering unless directed by a clinician.

Who Benefits Most

The evidence is strongest for adults with chronic stress or subclinical anxiety who are not currently taking psychiatric medications. Chandrasekhar et al. (2012) and Langade et al. (2019) both demonstrated meaningful improvements in this population. For individuals on antidepressants, the potential benefit is extrapolated, not proven.

Patients with medication-resistant anxiety sometimes seek adjunctive options. In these cases, ashwagandha may be considered as part of a broader integrative plan, but only with psychiatric oversight and clear monitoring protocols. The extract form matters: full-spectrum root extracts with standardized withanolide content (typically 5% or higher) are the forms used in positive trials. This is the rationale behind standardized products like Bio:sudo KSM-66 Reishi Restore, though again, the combination with antidepressants remains off-label and unstudied.

Those interested in ashwagandha's standalone effects on anxiety can read our deeper review: Ashwagandha for Anxiety: A Full Review of Human Clinical Trials.

Practical Takeaways

• Do not combine ashwagandha with antidepressants without telling your prescriber. The interaction data gap is real, and your clinician needs full visibility into everything you take.
• Start with the lowest effective dose if approved. Most positive trials used 300 mg twice daily of a standardized extract. Higher doses do not have better interaction safety data.
• Avoid starting during antidepressant initiation or tapering. These are periods of neurochemical instability. Adding any new supplement confounds symptom attribution.
• Monitor for sedation, activation, or gastrointestinal symptoms. These are the most commonly reported adverse effects in trials and could signal poor tolerability in combination therapy.
• Choose standardized extracts with disclosed withanolide content. Unstandardized powders vary widely in potency and may contain contaminants. For more on safety signals, see Ashwagandha Side Effects: What the Clinical Evidence and Case Reports Show.
• Do not use ashwagandha as a replacement for prescribed antidepressants. There is no evidence it treats major depressive disorder, and abrupt discontinuation of antidepressants carries significant risks.

Bottom Line

The question of Ashwagandha and Antidepressants does not have a definitive evidence-based answer because the combination has not been rigorously studied in controlled human trials. What we know is that ashwagandha has a plausible anxiolytic and stress-modulating profile in adults not taking psychiatric medications, and its mechanisms overlap with several neurochemical pathways that antidepressants also affect. Until dedicated interaction trials are conducted, the safest approach is transparency with your clinician, cautious dosing, and careful self-monitoring if combination use is approved.

References

1. Chandrasekhar K, et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." Indian Journal of Psychological Medicine. 2012;34(3):255–262. [Source]
2. Langade D, et al. "Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety." Medicine. 2019;98(37):e17186. [Source]
3. Wankhede S, et al. "Examining the effect of Withania somnifera supplementation on muscle strength and recovery." Journal of the International Society of Sports Nutrition. 2015;12:43. [Source]
4. Choudhary D, et al. "Efficacy and safety of ashwagandha (Withania somnifera) root extract in improving memory and cognitive functions." Journal of Dietary Supplements. 2017;14(6):599–612. [Source]
5. Pratte MA, et al. "An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha." Journal of Alternative and Complementary Medicine. 2014;20(12):901–908. [Source]

---

---